Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2012 2
2013 1
2014 1
2015 1
2016 1
2017 1
2018 1
2019 5
2020 3
2021 2
2022 5
2023 14
2024 18
2025 15

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yu mai (4 results)?
A new antibiotic selectively kills Gram-negative pathogens.
Imai Y, Meyer KJ, Iinishi A, Favre-Godal Q, Green R, Manuse S, Caboni M, Mori M, Niles S, Ghiglieri M, Honrao C, Ma X, Guo JJ, Makriyannis A, Linares-Otoya L, Böhringer N, Wuisan ZG, Kaur H, Wu R, Mateus A, Typas A, Savitski MM, Espinoza JL, O'Rourke A, Nelson KE, Hiller S, Noinaj N, Schäberle TF, D'Onofrio A, Lewis K. Imai Y, et al. Nature. 2019 Dec;576(7787):459-464. doi: 10.1038/s41586-019-1791-1. Epub 2019 Nov 20. Nature. 2019. PMID: 31747680 Free PMC article.
A selective antibiotic for Lyme disease.
Leimer N, Wu X, Imai Y, Morrissette M, Pitt N, Favre-Godal Q, Iinishi A, Jain S, Caboni M, Leus IV, Bonifay V, Niles S, Bargabos R, Ghiglieri M, Corsetti R, Krumpoch M, Fox G, Son S, Klepacki D, Polikanov YS, Freliech CA, McCarthy JE, Edmondson DG, Norris SJ, D'Onofrio A, Hu LT, Zgurskaya HI, Lewis K. Leimer N, et al. Among authors: imai y. Cell. 2021 Oct 14;184(21):5405-5418.e16. doi: 10.1016/j.cell.2021.09.011. Epub 2021 Oct 6. Cell. 2021. PMID: 34619078 Free PMC article.
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.
Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, Yamamoto S, Hara S, Miyajima K, Fukuokaya W, Enei Y, Iwatani K, Kayano S, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Tsuzuki S, Murakami M, Hata K, Shimomura T, Yamada H, Miki J, Kimura T. Urabe F, et al. Among authors: imai y. Jpn J Clin Oncol. 2024 Nov 2;54(11):1208-1213. doi: 10.1093/jjco/hyae098. Jpn J Clin Oncol. 2024. PMID: 39037966
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study.
Hara S, Urabe F, Tashiro K, Goto Y, Iwamoto Y, Ohtsuka T, Fukuokaya W, Imai Y, Iwatani K, Atsuta M, Mori K, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Murakami M, Tsuzuki S, Yanada BA, Hata K, Furuta A, Yamada H, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Hara S, et al. Among authors: imai y. Jpn J Clin Oncol. 2025 Feb 4;55(2):158-163. doi: 10.1093/jjco/hyae146. Jpn J Clin Oncol. 2025. PMID: 39426804
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Shimomura T, Yamada H, Miki J, Kimura T; JIKEI‐YAYOI Collaborative Group. Urabe F, et al. Among authors: imai y. Int J Urol. 2024 Nov;31(11):1248-1255. doi: 10.1111/iju.15546. Epub 2024 Jul 19. Int J Urol. 2024. PMID: 39031448
Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study.
Urabe F, Taneda Y, Uchida N, Kagawa H, Muramoto K, Goto Y, Koike Y, Hara S, Ohtsuka T, Nakazono M, Ishikawa M, Imai Y, Iwatani K, Kayano S, Atsuta M, Aikawa K, Tashiro K, Sasaki T, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Urabe F, et al. Among authors: imai y. Jpn J Clin Oncol. 2025 Jul 6;55(7):807-815. doi: 10.1093/jjco/hyaf060. Jpn J Clin Oncol. 2025. PMID: 40197493
Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management.
Goto Y, Urabe F, Ogihara Y, Nakata M, Nakano J, Fujiwara K, Hashimoto M, Koike Y, Iwamoto Y, Miyajima K, Fukuokaya W, Iwatani K, Imai Y, Inaba Y, Ito K, Yanagisawa T, Murakami M, Tashiro K, Watanabe K, Miki J, Kimura T; JIKEI‐YAYOI Collaborative Group. Goto Y, et al. Among authors: imai y. BJU Int. 2025 Jul 19. doi: 10.1111/bju.16860. Online ahead of print. BJU Int. 2025. PMID: 40682449
Evybactin is a DNA gyrase inhibitor that selectively kills Mycobacterium tuberculosis.
Imai Y, Hauk G, Quigley J, Liang L, Son S, Ghiglieri M, Gates MF, Morrissette M, Shahsavari N, Niles S, Baldisseri D, Honrao C, Ma X, Guo JJ, Berger JM, Lewis K. Imai Y, et al. Nat Chem Biol. 2022 Nov;18(11):1236-1244. doi: 10.1038/s41589-022-01102-7. Epub 2022 Aug 22. Nat Chem Biol. 2022. PMID: 35996001 Free PMC article.
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study.
Urabe F, Kagawa H, Yanagisawa T, Takahashi H, Hashimoto M, Hara S, Fukuokaya W, Imai Y, Iwatani K, Igarashi T, Atsuta M, Tashiro K, Murakami M, Tsuzuki S, Yanada BA, Yamamoto T, Hata K, Yamada H, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Urabe F, et al. Among authors: imai y. Prostate Int. 2025 Mar;13(1):41-48. doi: 10.1016/j.prnil.2024.11.003. Epub 2024 Nov 22. Prostate Int. 2025. PMID: 40213352 Free PMC article.
64 results